Table 2 Impact of clinical, hematological factors and prognostic score on clinical outcomes in recurrence or metastatic head and neck cancer patients treated with nivolumab.

ECOG PS

0, 1

102

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

2, 3

24

1.90

1.18–3.06

0.008

2.17

1.30–3.63

0.003

3.14

1.77–5.57

< 0.001

2.94

1.55–5.55

< 0.001

IrAE

Without

85

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

With

41

0.55

0.36–0.84

0.006

0.52

0.34–0.80

0.003

0.49

0.27–0.87

0.016

0.47

0.26–0.86

0.015

Modified Glasgow Prognostic Score

0

70

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

1, 2

47

2.02

1.34–3.03

< 0.001

2.37

1.55–3.63

< 0.001

2.40

1.41–4.10

0.001

2.51

1.45–4.35

< 0.001

Relative eosinophil count

< 1.5

71

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

≥ 1.5

53

0.68

0.46–1.00

0.049

0.68

0.46–1.00

0.048

0.51

0.31–0.86

0.011

0.49

0.29–0.83

0.008

Neutrophil/lymphocyte ratio

< 5

71

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

≥ 5

53

1.28

0.87–1.88

0.218

1.32

0.89–1.95

0.167

1.54

0.93–2.56

0.094

1.56

0.92–2.65

0.096

Platelet/lymphocyte ratio

< 253

62

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

≧ 253

63

1.04

0.71–1.53

0.830

1.10

0.75–1.63

0.626

1.37

0.82–2.29

0.236

1.37

0.80–2.35

0.246

Best overall response

SD, PD

97

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

CR, PR

29

0.19

0.11–0.33

< 0.001

0.17

0.10–0.30

< 0.001

0.18

0.08–0.41

< 0.001

0.18

0.07–0.42

< 0.001

Prognostic score

0–1

27

1.00

–

–

1.00

–

–

1.00

–

–

1.00

–

–

2–3

61

2.78

1.60–4.83

< 0.001

3.44

1.95–6.06

< 0.001

6.67

2.04–21.90

< 0.001

7.63

2.29–25.37

< 0.001

4–5

28

6.11

3.22–11.61

< 0.001

7.77

3.98–15.15

< 0.001

15.06

4.43–51.13

< 0.001

14.66

4.28–50.22

< 0.001

P_trend < 0.001

P_trend < 0.001

P_trend < 0.001

P_trend < 0.001